Tenderwize
Back to tender search

Conclusion of non-exclusive drug discount agreement according to §130a(8) SGB V via Open-House model for the active substance Trientin (ATC: A16AX12)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 39 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Trientin (ATC-Code nach WHO: A16AX12)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

40 / 100

Complexity

30 / 100

Risk factors

No minimum volume guaranteed; actual prescriptions depend on doctors and pharmacies. Revenue may be negligible.

AOK PLUS may terminate the Open-House procedure if exclusive agreements are concluded, typically 8-12 months after publ...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Non-exclusive drug discount agreements for the active substance Trientin (ATC: A16AX12)
  • Open-House model allowing any eligible pharmaceutical entrepreneur to participate
Show full summary

This tender is a non-exclusive drug discount agreement (Open-House model) for the active substance Trientin (ATC: A16AX12) organized by AOK PLUS. It is not a traditional public procurement but is published for transparency. Any eligible pharmaceutical entrepreneur can participate at any time until 30 September 2026, subject to rolling submission deadlines. No minimum purchase volumes are guaranteed, and the agreement may be terminated early if exclusive agreements are concluded.

Risks

No minimum volume guaranteed; actual prescriptions depend on doctors and pharmacies. Revenue may be negligible.

AOK PLUS may terminate the Open-House procedure if exclusive agreements are concluded, typically 8-12 months after publ...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG

Eligibility

  • Must submit self-declaration on absence of exclusion grounds ($$§123,124 GWB)

Administrative

  • Must submit declaration on compliance with EU Russia sanctions (Regulation 833/2014)

Requirements may be incomplete.

Award Criteria

Lot 1

No specific award criteria disclosed; participation is based on acceptance of the framework terms.

Buyer

Location

Erfurt, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Conclusion of non-exclusive drug discount agreement according to §130a(8) SGB V via Open-House model for the active substance Trientin (ATC: A16AX12)

Non-exclusive framework agreement for drug discounts on Trientin. Participation open to all eligible pharmaceutical companies. No minimum volumes. Agreement ends 30 September 2026.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Sep 2025 - Sep 2026

Category

Pharmaceutical products

Award Criteria

No specific award criteria disclosed; participation is based on acceptance of the framework terms.

Deadline

Deadline Sep 30, 2026

Procurement Details

Publication date
31 Jul 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
506508-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3